A Phase 4 interventional study of FPNS and FFNS in Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline. Completed at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-09.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing fluticasone in Rhinitis, Allergic, Perennial — 1 open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Perennial.
Among the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, this one is the 8th largest by enrollment, is one of 4 that started in 2007, is one of 7 in phase 4, and was the 10th registered.
178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.
Browse Rhinitis, Allergic, Perennial studies →1 of the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial is open now, in 1 country. Recruiting first, the newest first:
HALEON · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 360 is above the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.
Median enrollment 288 across the 21 interventional studies. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 21 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 28 finished, 13 (46%) have results posted.
Among the 28 studies in Rhinitis, Allergic, Perennial by GlaxoSmithKline, this one is the 7th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2007, is one of 7 in phase 4, and was the 16th registered.
GlaxoSmithKline’s Rhinitis, Allergic, Perennial studies by the year they started, since 2005.
1 of the studies testing fluticasone in Rhinitis, Allergic, Perennial that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07817134HALEONA Study to Visualize Multi-Symptom Allergy in Adults With Seasonal Allergic Rhinitis | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 28 in Rhinitis, Allergic, Perennial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this replicate study to FFU105924 is to provide data on subject preference of FFNS as compared with FPNS.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy, Patient Preference and Experience of One-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis (FFU105927)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
fluticasone furoate nasal spray, fluticasone propionate nasal spray
Drug: FPNS · Drug: FFNS
fluticasone propionate nasal spray, fluticasone furoate nasal spray
Drug: FPNS · Drug: FFNS
placebo nasal spray matching fluticasone furoate nasal spray, placebo nasal spray matching fluticasone propionate nasal spray
Drug: placebo FFNS · Drug: placebo FPNS
placebo nasal spray matching fluticasone propionate nasal spray, placebo nasal spray matching fluticasone furoate nasal spray
Drug: placebo FFNS · Drug: placebo FPNS
fluticasone propionate nasal spray
Also known as: fluticasone propionate, fluticasone furoate
fluticasone furoate nasal spray
placebo nasal spray matching fluticasone furoate nasal spray
placebo nasal spray matching fluticasone propionate nasal spray
Comparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Each Treatment Period of Active Drug Nasal Sprays Versus Placebos
Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12. The mean of AM and PM scores were used.
Time frame: Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)
Subject Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Scent/Odor
Subjects assessed preference of scent/odor for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Subject could also choose "I have no preference."
Time frame: End of Crossover Period (Day 22)
Comparation of Mean Change From Baseline Over Each Treatment Period in Daytime Reflective Total Nasal Symptom Scores (D r-TNSS) for Active Drug Nasal Sprays Versus Placebos
Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe.
Time frame: Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)
Comparision of Mean Change From Baseline Over Each Treatment Period in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) for Active Drug Nasal Sprays Versus Placebos
Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12.
Time frame: Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)
Subject Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) on Preference for: Leaking Out of Nose/Down Throat
Subjects assessed preference over leaking out of nose/down throat for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Subject could also choose "I have no preference."
Time frame: End of Crossover Period (Day 22)
Subject Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) on Preference for: Ease of Use
Subjects assessed preference over ease of use for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Subject could also choose "I have no preference."
Time frame: End of Crossover Period (Day 22)
Subject Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) on Preference for: Gentleness of Mist
Subjects assessed preference over gentleness of mist for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Subject could also choose "I have no preference."
Time frame: End of Crossover Period (Day 22)
| Milestone | Fluticasone Furoate NS/Fluticasone Propionate NS | Placebo FF/FP | Fluticasone Propionate NS/Fluticasone Furoate NS | Placebo FP/FF |
|---|---|---|---|---|
| Started | 91 | 86 | 90 | 93 |
| Completed | 89 | 86 | 89 | 93 |
| Not completed | 2 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 |
| Withdrew: Sponsor request due to missed visit | 1 | 0 | 0 | 0 |
| Milestone | Fluticasone Furoate NS/Fluticasone Propionate NS | Placebo FF/FP | Fluticasone Propionate NS/Fluticasone Furoate NS | Placebo FP/FF |
|---|---|---|---|---|
| Started | 89 | 86 | 89 | 93 |
| Completed | 69 | 72 | 75 | 88 |
| Not completed | 20 | 14 | 14 | 5 |
| Withdrew: Adverse event | 2 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 |
| Withdrew: Failed to meet continuation criteria | 14 | 11 | 9 | 3 |
| Withdrew: Out of pollen area > 48 hours | 1 | 0 | 0 | 0 |
| Withdrew: Participating in study at another site | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliant | 0 | 1 | 0 | 0 |
| Withdrew: Per doctors request | 0 | 1 | 0 | 0 |
| Withdrew: Subject randomized in error | 0 | 0 | 1 | 0 |
| Withdrew: Prohibited medications | 0 | 0 | 1 | 0 |
| Milestone | Fluticasone Furoate NS/Fluticasone Propionate NS | Placebo FF/FP | Fluticasone Propionate NS/Fluticasone Furoate NS | Placebo FP/FF |
|---|---|---|---|---|
| Started | 69 | 72 | 75 | 88 |
| Completed | 69 | 71 | 74 | 86 |
| Not completed | 0 | 1 | 1 | 2 |
| Withdrew: Failed to meet continuation criteria | 0 | 0 | 0 | 1 |
| Withdrew: Subject randomized in error | 0 | 1 | 0 | 0 |
| Withdrew: Per doctors request | 0 | 0 | 1 | 0 |
| Withdrew: Subject misrandomized | 0 | 0 | 0 | 1 |
| Milestone | Fluticasone Furoate NS/Fluticasone Propionate NS | Placebo FF/FP | Fluticasone Propionate NS/Fluticasone Furoate NS | Placebo FP/FF |
|---|---|---|---|---|
| Started | 69 | 71 | 74 | 86 |
| Completed | 69 | 71 | 74 | 85 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Subject randomized in error | 0 | 0 | 0 | 1 |
Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12. The mean of AM and PM scores were used.
| Scores on a scale | Fluticasone Furoate NS/Fluticasone Propionate NS | Placebo FF/FP | Fluticasone Propionate NS/Fluticasone Furoate NS | Placebo FP/FF |
|---|---|---|---|---|
| Change from Baseline Treatment Period 1 | -2.7 ± 0.26 | -1.7 ± 0.22 | -2.2 ± 0.23 | -1.5 ± 0.22 |
| Change from Baseline Treatment Period 2 | -2.7 ± 0.29 | -2.1 ± 0.27 | -2.3 ± 0.30 | -1.7 ± 0.26 |
Subjects assessed preference of scent/odor for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Subject could also choose "I have no preference."
| Participants | Fluticasone Furoate NS/Fluticasone Propionate NS | Fluticasone Propionate NS/Fluticasone Furoate NS | Total |
|---|---|---|---|
| Perferred - Fluticasone Furoate Nasal Spray | 41 | 41 | 82 |
| Perferred - Fluticasone Propionate Nasal Spray | 18 | 20 | 38 |
| No Preference | 9 | 13 | 22 |
Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe.
| Scores on a scale | Fluticasone Furoate NS/Fluticasone Propionate NS | Placebo FF/FP | Fluticasone Propionate NS/Fluticasone Furoate NS | Placebo FP/FF |
|---|---|---|---|---|
| Change from Baseline- Treatment Period 1 | -2.9 ± 0.27 | -1.6 ± 0.22 | -2.4 ± 0.25 | -1.7 ± 0.23 |
| Change from Baseline- Treatment Period 2 | -2.7 ± 0.29 | -2.2 ± 0.28 | -2.4 ± 0.32 | -1.9 ± 0.27 |
Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12.
| Scores on a scale | Fluticasone Furoate NS/Fluticasone Propionate NS | Placebo FF/FP | Fluticasone Propionate NS/Fluticasone Furoate NS | Placebo FP/FF |
|---|---|---|---|---|
| Change from Baseline- Treatment Period 1 | -2.7 ± 0.28 | -1.7 ± 0.23 | -2.1 ± 0.25 | -1.4 ± 0.24 |
| Change from Baseline- Treatment Period 2 | -2.7 ± 0.32 | -2.0 ± 0.29 | -2.2 ± 0.32 | -1.6 ± 0.28 |
Subjects assessed preference over leaking out of nose/down throat for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Subject could also choose "I have no preference."
| Participants | Fluticasone Furoate NS/Fluticasone Propionate NS | Fluticasone Propionate NS/Fluticasone Furoate NS | Total |
|---|---|---|---|
| Preferred - Fluticasone Furoate Nasal Spray | 45 | 39 | 84 |
| Preferred - Fluticasone Propionate Nasal Spray | 16 | 14 | 30 |
| No Preference | 8 | 20 | 28 |
Subjects assessed preference over ease of use for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Subject could also choose "I have no preference."
| Participants | Fluticasone Furoate NS/Fluticasone Propionate NS | Fluticasone Propionate NS/Fluticasone Furoate NS | Total |
|---|---|---|---|
| Preferred - Fluticasone Furoate Nasal Spray | 28 | 30 | 58 |
| Preferred - Fluticasone Propionate Nasal Spray | 22 | 32 | 54 |
| No Preference | 19 | 12 | 31 |
Subjects assessed preference over gentleness of mist for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Subject could also choose "I have no preference."
| Participants | Fluticasone Furoate NS/Fluticasone Propionate NS | Fluticasone Propionate NS/Fluticasone Furoate NS | Total |
|---|---|---|---|
| Preferred - Fluticasone Furoate Nasal Spray | 38 | 44 | 82 |
| Preferred - Fluticasone Propionate Nasal Spray | 17 | 20 | 37 |
| No Preference | 14 | 10 | 24 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluticasone Furoate Nasal Spray | — | 0/166 (0%) | 7/166 (4.2%) |
| Fluticasone Propionate Nasal Spray | — | 0/159 (0%) | 14/159 (8.8%) |
| Placebo - FF | — | 0/174 (0%) | 12/174 (6.9%) |
| Placebo -FP | — | 0/166 (0%) | 12/166 (7.2%) |
| Event | Fluticasone Furoate Nasal Spray | Fluticasone Propionate Nasal Spray | Placebo - FF | Placebo -FP |
|---|---|---|---|---|
| HeadacheNervous system disorders | 7/166 | 14/159 | 12/174 | 12/166 |
| Age, Continuous(years) | Fluticasone Furoate NS/Fluticasone Propionate NS | Placebo FF/FP | Fluticasone Propionate NS/Fluticasone Furoate NS | Placebo FP/FF | Total |
|---|---|---|---|---|---|
| Mean | 38.8 ± 12.25 | 38 ± 11.54 | 37.2 ± 12.55 | 38.9 ± 11.39 | 38.3 ± 11.91 |
| Gender(Participants) | Fluticasone Furoate NS/Fluticasone Propionate NS | Placebo FF/FP | Fluticasone Propionate NS/Fluticasone Furoate NS | Placebo FP/FF | Total |
|---|---|---|---|---|---|
| Female | 49 | 51 | 60 | 54 | 214 |
| Male | 42 | 35 | 30 | 39 | 146 |
| Race/Ethnicity, Customized(participants) | Fluticasone Furoate NS/Fluticasone Propionate NS | Placebo FF/FP | Fluticasone Propionate NS/Fluticasone Furoate NS | Placebo FP/FF | Total |
|---|---|---|---|---|---|
| African American/African Heritage | 15 | 11 | 23 | 21 | 70 |
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian: Central/South Asian Heritage | 1 | 2 | 1 | 3 | 7 |
| Asian: Japanese/East-Southeast Asian Heritage | 2 | 4 | 2 | 4 | 12 |
| Native Hawaiian or other Pacific Islander | 2 | 1 | 0 | 1 | 4 |
| White | 67 | 66 | 63 | 64 | 260 |
| African American/African Heritage & Asian | 1 | 0 | 0 | 0 | 1 |
| African American/African Heritage & White | 0 | 0 | 1 | 0 | 1 |
| Unknown | 2 | 2 | 0 | 0 | 4 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Aug 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Rhinitis, Allergic, Perennial →